Table 1 Patient demographics
From: CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin
| CBR3 Genotype | |||||
|---|---|---|---|---|---|
| AA | AG | GG | All Patients | p Valve | |
| (N = 13) | (N = 53) | (N = 26) | (N = 92) | ||
| n (%) | n (%) | n (%) | n (%) | ||
| Chemotherapy, mean ± SD | |||||
| Anthracycline dose, mg | 461 ± 77 | 424 ± 60 | 439 ± 49 | 433 ± 61 | 0.168 |
| Cytoxan dose, mg | 4645 ± 827 | 4315 ± 579 | 4397 ± 517 | 4384 ± 615 | 0.979 |
| Treatment days | 4 ± 0 | 3.9 ± 0.37 | 4.0 ± 0.19 | 3.9 ± 0.4 | 0.2849 |
| Trastuzumab (adjuvant) | 1 (8%) | 4 (8%) | 3 (11%) | 8 (9%) | 0.859 |
| Chest radiation, left-side | 6 (46%) | 28 (53%) | 12 (46%) | 46 (50%) | 0.732 |
| Sex, female | 11 (85%) | 53 (100%) | 26 (100%) | 90 (98%) | 0.002* |
| Age, years | |||||
| Mean ± SD | 55 ± 12 | 51 ± 12 | 51 ± 12 | 52 ± 11 | 0.692 |
| Range | 33–76 | 24–73 | 32–73 | 24–76 | |
| Race | |||||
| Caucasian | 10 (77%) | 48 (91%) | 23 (89%) | 81 (88%) | 0.396 |
| African American | 1 (8%) | 4 (8%) | 3 (11%) | 8 (9%) | |
| Hispanic | 0 | 0 | 0 | 0 | |
| Asian | 1 (8%) | 0 | 0 | 1 (1%) | |
| Mixed | 1 (8%) | 1 (2%) | 0 | 2 (2%) | |
| Comorbidities | |||||
| Hypertension | 5 (38%) | 15 (28%) | 5 (19%) | 25 (27%) | 0.386 |
| Diabetes | 1 (8%) | 3 (6%) | 2 (7%) | 6 (6%) | 0.938 |
| Hyperlipidemia | 6 (46%) | 9 (17%) | 5 (19%) | 21 (23%) | 0.069 |
| Smoking history | 4 (31%) | 21 (40%) | 10 (37%) | 35 (38%) | 0.838 |
| Medication | |||||
| ACE inhibitor | 1 (8%) | 5 (9%) | 3 (11%) | 9 (10%) | 0.126 |
| ARB | 2 (15%) | 3 (6%) | 2 (7%) | 7 (8%) | 0.492 |
| Beta blocker | 2 (15%) | 4 (8%) | 1 (4%) | 7 (8%) | 0.423 |
| Statin | 4 (31%) | 6 (11%) | 0 (0%) | 10 (11%) | 0.014* |